Cardax Inc
OTC:CDXI

Watchlist Manager
Cardax Inc Logo
Cardax Inc
OTC:CDXI
Watchlist
Price: 0.0001 USD Market Closed
Market Cap: 80.3 USD

Cardax Inc
Free Cash Flow

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Cardax Inc
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
Cardax Inc
OTC:CDXI
Free Cash Flow
-$1.8m
CAGR 3-Years
5%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Free Cash Flow
$19.6B
CAGR 3-Years
3%
CAGR 5-Years
1%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Free Cash Flow
$15.3B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
31%
Pfizer Inc
NYSE:PFE
Free Cash Flow
$10.4B
CAGR 3-Years
-24%
CAGR 5-Years
0%
CAGR 10-Years
-3%
Merck & Co Inc
NYSE:MRK
Free Cash Flow
$13B
CAGR 3-Years
-5%
CAGR 5-Years
14%
CAGR 10-Years
8%
Eli Lilly and Co
NYSE:LLY
Free Cash Flow
$6.4B
CAGR 3-Years
6%
CAGR 5-Years
5%
CAGR 10-Years
14%
No Stocks Found

Cardax Inc
Glance View

Market Cap
80.3 USD
Industry
Pharmaceuticals

Cardax, Inc. is a development stage biopharmaceutical company, which engages in development of pharmaceuticals for chronic diseases driven by inflammation. The company is headquartered in Honolulu, Hawaii and currently employs 10 full-time employees. The company went IPO on 2012-01-30. The firm has a commercial business unit that markets dietary supplements for inflammatory health. The firm's product platform consists of CDX-101, astaxanthin pharmaceutical candidate, that is being developed for cardiovascular inflammation and dyslipidemia, with a target initial indication of severe hypertriglyceridemia. CDX-301, the Company’s zeaxanthin pharmaceutical candidate, is being developed for macular degeneration. Its pharmaceutical candidates are in pre-clinical development, including the planning of investigational new drug (IND) enabling studies. ZanthoSyn is a physician recommended astaxanthin dietary supplement for inflammatory health. The firm sells ZanthoSyn primarily through wholesale and e-commerce channels.

CDXI Intrinsic Value
Not Available

See Also

What is Cardax Inc's Free Cash Flow?
Free Cash Flow
-1.8m USD

Based on the financial report for Dec 31, 2020, Cardax Inc's Free Cash Flow amounts to -1.8m USD.

What is Cardax Inc's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-4%

Over the last year, the Free Cash Flow growth was 49%. The average annual Free Cash Flow growth rates for Cardax Inc have been 5% over the past three years , -4% over the past five years .

Back to Top